Gefitinib–trastuzumab combination on hormone-refractory prostate cancer xenograft

This publication has 15 references indexed in Scilit:

• Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control
  JNCI Journal of the National Cancer Institute, 2003
• Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures
  Zeitschrift für Krebsforschung und Klinische Onkologie, 2003
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
  Journal of Clinical Oncology, 2002
• HER-2/NEU EXPRESSION IN PROSTATE CANCER: HIGH LEVEL OF EXPRESSION ASSOCIATED WITH EXPOSURE TO HORMONE THERAPY AND ANDROGEN INDEPENDENT DISEASE
  Journal of Urology, 2001
• Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
  JNCI Journal of the National Cancer Institute, 2000
• From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
  Proceedings of the National Academy of Sciences, 1999
• Natural History of Progression After PSA Elevation Following Radical Prostatectomy
  JAMA, 1999
• Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer
  Journal of Clinical Oncology, 1999
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
  Nature Medicine, 1999
• Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate
  Cancer Letters, 1998